Employees Retirement System of Texas Sells 12,789 Shares of Johnson & Johnson $JNJ

Key Points

• Employees Retirement System of Texas reduced its Johnson & Johnson stake by 35.4% in the fourth quarter, selling 12,789 shares and leaving it with 23,345 shares worth about $4.83 million.
• Johnson & Johnson recently beat quarterly expectations, reporting $2.70 EPS versus $2.68 expected and $24.06 billion in revenue, while also raising its FY 2026 EPS guidance to $11.45-$11.65.
• The company increased its quarterly dividend to $1.34 per share from $1.30, and analysts remain generally positive with an average rating of “Moderate Buy” and a consensus price target of $253.04.

Employees Retirement System of Texas cut its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 35.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,345 shares of the company's stock after selling 12,789 shares during the quarter. Employees Retirement System of Texas' holdings in Johnson & Johnson were worth $4,831,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Expressive Wealth LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $941,000. Strategic Financial Services Inc. increased its stake in Johnson & Johnson by 0.5% during the 4th quarter. Strategic Financial Services Inc. now owns 8,995 shares of the company's stock worth $1,862,000 after purchasing an additional 45 shares in the last quarter. GHE LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $2,367,000. Syverson Strege & Co increased its stake in Johnson & Johnson by 3.4% during the 4th quarter. Syverson Strege & Co now owns 6,616 shares of the company's stock worth $1,369,000 after purchasing an additional 218 shares in the last quarter. Finally, TrustBank bought a new position in Johnson & Johnson during the 4th quarter worth about $518,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $231.38 on Thursday. The stock has a market capitalization of $556.97 billion, a price-to-earnings ratio of 26.75, a PEG ratio of 2.25 and a beta of 0.27. The business has a 50-day moving average of $233.41 and a 200-day moving average of $224.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a fifty-two week low of $149.04 and a fifty-two week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. During the same quarter last year, the company earned $2.77 EPS. Johnson & Johnson's revenue for the quarter was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a $1.34 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio (DPR) is 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson announced it will hold its second-quarter earnings conference call on July 15, reinforcing near-term focus on results, guidance, and management commentary. Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
• Positive Sentiment: DePuy Synthes, J&J’s orthopedic business, struck an exclusive distribution deal for the NOVOSIS bone graft product, adding another growth-oriented medtech move. DePuy Synthes secures exclusive NOVOSIS bone graft distribution partnership
• Positive Sentiment: Market commentary highlighted J&J as one of several large-cap pharma stocks worth holding as the industry recovery accelerates, supporting sentiment toward the stock. 4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
• Positive Sentiment: J&J was reported to have an average brokerage recommendation of “Moderate Buy,” suggesting analysts remain constructive on the shares. Johnson & Johnson Receives Average Recommendation of Moderate Buy from Brokerages
• Neutral Sentiment: J&J also presented at Bernstein’s Strategic Decisions Conference, but the transcript does not point to a fresh, stock-moving surprise by itself. Johnson & Johnson Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
• Negative Sentiment: Talc litigation remains an overhang, with new verdict headlines reinforcing legal risk that could pressure valuation multiples. Assessing Johnson & Johnson Valuation After Guidance Raise Growth Initiatives And Talc Litigation Update
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with pharma and healthcare stocks described as a drag on the market in recent trading. Dow Gives Back Early Gains. Healthcare Stocks Are a Drag.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on JNJ shares. Wells Fargo & Company increased their target price on Johnson & Johnson from $240.00 to $263.00 and gave the stock an "overweight" rating in a report on Wednesday, April 15th. Sanford C. Bernstein increased their target price on Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a report on Wednesday, April 15th. Guggenheim increased their target price on Johnson & Johnson from $244.00 to $266.00 and gave the stock a "buy" rating in a report on Monday, April 20th. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a report on Wednesday, April 15th. Finally, Daiwa Securities Group raised their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an "outperform" rating in a research note on Thursday, April 16th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.